Disclosed herein are embodiments of nanoparticle composites that comprise covalently coupled stabilizing agent molecules that improve stability of the nanoparticle composites and allow for tight packing of lipids and/or membranes. The nanoparticle composites can further comprise inhibition inhibitors and/or lipid components that interact to form a hybrid lipid bilayer membrane around the nanoparticle core. The nanoparticle composites can be coupled to drugs, targeting moieties, and imaging moieties. The nanoparticle composites can be used for in vivo drug deliver, disease diagnosis/treatment, and imaging.

Provided are DNA-coated nanoparticles (DNA-NPS), superparamagnetic nanoparticles (DNA-SPNs), and superparamagnetic iron oxide nanopa rticles (DNA-SPIONs) as efficient imaging agents for targeting and imaging atherosclerotic lesions and treating atherosclerotic disease. The DNA-NS, DNA-SPNs, and DNA-SPIONs can enter macrophage cells via the Class A scavenger receptor (SR-A)-mediated pathways and can be used to specifically target atheroscleortic plaques.

Provided are DNA-coated nanoparticles (DNA-NPS), superparamagnetic nanoparticles (DNA-SPNs), and superparamagnetic iron oxide nanoparticles (DNA-SPIONs) as efficient imaging agents for targeting and imaging atherosclerotic lesions and treating atherosclerotic disease. The DNA-NS, DNA-SPNs, and DNA-SPIONs can enter macrophage cells via the Class A scavenger receptor (SR-A)-mediated pathways and can be used to specifically target atheroscleortic plaques.

Disclosed herein are embodiments of nanoparticle composites that comprise covalently coupled stabilizing agent molecules that improve stability of the nanoparticle composites and allow for tight packing of lipids and/or membranes. The nanoparticle composites can further comprise inhibition inhibitors and/or lipid components that interact to form a hybrid lipid bilayer membrane around the nanoparticle core. The nanoparticle composites can be coupled to drugs, targeting moieties, and imaging moieties. The nanoparticle composites can be used for in vivo drug deliver, disease diagnosis/treatment, and imaging.

This invention relates to a method to assess nodal disease by magnetic resonance imaging with a contrast agent. The contrast agent comprises biofunctional magnetic nanoparticles coated with polymers outside the iron core and conjugated with antibodies specific to the tumor type to be assessed. Images produced from this magnetic resonance imaging with a contrast agent show heterogenous hypo intensity or heterogenous architecture in regions where binding by the antibodies is present.

An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of Lewis A or Lewis B or its mimetics. Lewis A and Lewis B and its mimetics are also provided for use in the therapeutic treatment of inflammatory diseases, autoimmune diseases and cancer.

Provided are a preparation method of iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles, iron oxide-based nanoparticles prepared by the same, and a T1 contrast agent including the same. More particularly, the disclosure describes a method for preparation of iron oxide nanoparticles having a extremely small and uniform size of 4 nm or less based on thermal decomposition of iron oleate complex, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles prepared by the same, and a T1 contrast agent including iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles.

The present invention provides derivatized magnetic nanoparticles, methods for making such nanoparticles, and methods for their use.